Pharma Globenewswire

Multiple Myeloma: Comprehensive Market Intelligence, Epidemiology, and Forecast Analysis Through 2034

10 April 2026

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2034” analysis provides comprehensive understanding of Multiple Myeloma, encompassing historical and projected epidemiology alongside market trajectories across the United States, EU4 nations (Germany, Spain, Italy, France), the United Kingdom, and Japan. The latest

Uncategorised

Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch

9 April 2026

Eczema Major players in the pipeline include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others. DelveInsight’s “Eczema Pipeline Insights 2026” report delivers an extensive analysis

Clinical Trials·Reports

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

9 April 2026

DelveInsight’s “Lassa Fever – Pipeline Insight, 2026” provides a detailed view of the evolving pipeline, emphasizing efforts to deliver first-in-class therapies and vaccines to endemic populations. The report highlights global R&D activity, platform technologies, and regulatory incentives accelerating development timelines.Lassa Fever, an

Clinical Trials·Reports

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

9 April 2026

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise in aging populations is significantly increasing the at-risk patient base.

Clinical Trials·Reports·Uncategorised

Migraine Clinical Trial Analysis Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space

9 April 2026

The migraine therapeutics market is experiencing strong momentum as rising global prevalence, better diagnostic recognition, and expanding patient awareness steadily grow the treated population. Adoption of targeted therapies such as CGRP inhibitors and gepants continues to accelerate, driven by their superior tolerability

Uncategorised

Groundbreaking Growth in Esophageal Cancer Market Forecast Through 2034 Driven by Innovation, Diagnosis, and Therapeutic Advances Worldwide

9 April 2026

Esophageal Cancer Market The Esophageal Cancer market is poised for transformative growth through 2034, with strong projected expansion in the 7MM – the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan. Fueled by rising incidence rates, enhanced diagnostic

Uncategorised

Sickle Cell Disease Treatment Pipeline: Detailed 2026 Insights

8 April 2026

DelveInsight’s “Sickle Cell Disease Pipeline Insights 2026” analysis delivers extensive perspectives on 55+ organizations and 60+ therapeutic candidates in the Sickle Cell Disease Competitive environment. It encompasses Sickle Cell Disease Pipeline Treatment evaluation by product classification, developmental phase, administration route, and molecular

Uncategorised

Alzheimer’s Disease Market Insight, Epidemiology And Market Forecast 2034

8 April 2026

DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast 2034” offers an in-depth exploration of the complex landscape of Alzheimer’s Disease (AD) across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report delivers a robust

Uncategorised

KRAS Inhibitors Market Poised for Explosive Growth: Projected to Surge from USD 526 Million in 2025 to USD 7,847 Million by 2034

8 April 2026

KRAS Inhibitors Market Summary The KRAS Inhibitors market is on the cusp of a transformative decade, driven by unprecedented scientific breakthroughs, regulatory milestones, and a rapidly expanding pipeline of targeted oncology therapies. Valued at approximately USD 526 million across the Seven Major

Latest

Multiple Myeloma: Comprehensive Market Intelligence, Epidemiology, and Forecast Analysis Through 2034

Eczema Pipeline 2026 Outlook: 100+ Clinical Assets and 3 Key Late-Stage Candidates to Watch

Lassa Fever Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA, and Companies by DelveInsight

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain

Migraine Clinical Trial Analysis Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space

Groundbreaking Growth in Esophageal Cancer Market Forecast Through 2034 Driven by Innovation, Diagnosis, and Therapeutic Advances Worldwide

Sickle Cell Disease Treatment Pipeline: Detailed 2026 Insights

Alzheimer’s Disease Market Insight, Epidemiology And Market Forecast 2034

KRAS Inhibitors Market Poised for Explosive Growth: Projected to Surge from USD 526 Million in 2025 to USD 7,847 Million by 2034

Recent Posts

Banner

Newsletter

Authors